Altamira Therapeutics (Auris Medical) Priced, Nasdaq: CYTO
Biotech developing treatments for tinnitus and other inner ear disorders.
Industry: Health Care
First Day Return: 0.0%
Industry: Health Care
CYTO
Biotech developing treatments for tinnitus and other inner ear disorders.
| IPO Data | |
|---|---|
| IPO File Date | 06/30/2014 |
| Offer Price | $6.00 |
| Price Range $6.00 - $6.00 | |
| Offer Shares (mm) | 9.4 |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 08/05/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Zug, Switzerland |
| Founded | 2003 |
| Employees at IPO | 13 |
| Website www.aurismedical.com | |
IPO News for Altamira Therapeutics (Auris Medical)
Altamira Therapeutics (Auris Medical) (CYTO) Performance
